摘要
目的:观察早期应用奥扎格雷治疗急性脑梗死的神经功能改善情况及对患者血浆超敏C反应蛋白(hs-CRP)和白细胞介素6(IL-6)的影响。方法:将60例急性脑梗死患者随机均分为对照组和奥扎格雷组。2组患者均给予相同的抗高血压、降颅压、脑细胞活化剂、阿司匹林抗凝等治疗,奥扎格雷组加用奥扎格雷注射液80mg,静脉滴注,bid,连用1周。观察治疗前、后血浆hs-CRP和IL-6的变化,并进行临床神经功能缺损评价及不良反应的观察。结果:治疗1周后,2组患者血浆hs-CRP和IL-6含量、神经功能缺损评分均明显下降(P<0.01或P<0.05),且与对照组比较,奥扎格雷组下降幅度更明显(P<0.05)。2组均未见不良反应发生。结论:急性脑梗死早期应用奥扎格雷治疗,能明显改善患者hs-CRP及IL-6水平,改善脑梗死部位缺血、缺氧和神经功能缺损状态,且安全性好。
OBJECTIVE： To observe the clinical efficacy of ozagrel on high-sensitivity C-reactive protein （hs-CRP） and inter- leukin-6 （IL-6） in patients with acute cerebral infarction in the early phase. METHODS： 60 patients with acute cerebral infarction were randomly divided into control group and ozagrel group. All patients received the treatment of antihypertension, lowering intra- cranial hypertension, activator of brain cells and anticoagulation by taking aspirin. And oazgrel group additionally got treatment of continuous intravenous infusion of ozagrel 80 mg, twice a day, for 1 week. The changes of plasma level of hs-CRP and IL-6 were observed before and after treatment, and the neural function deficit evaluation and the record of adverse reaction were all conduct- ed. RESULTS： The levels of hs-CRP, IL-6, and neural function defects score of both groups decreased significantly after 1 week treatment （P〈0.01 or P〈0.05）, and that of ozagrel group decreased more obviously （P〈0.05）. No obvious adverse drug reaction was observed in ozagrel group. CONCLUSIONS： There is a certain clinic effect of ozagrel in the treatment of acute cerebral infarc- tion in the early phase. It can improve the levels of hs-CRP and IL-6, the hypoxia and ischemia of cerebral infarction area and the neural fianction deficit with low ADR.
出处
《中国药房》
CAS
CSCD
2012年第4期315-316,共2页
China Pharmacy
